Thursday, 15 October 2026European Markets

CNOVA Stock 13.74% Up Today

Loading stream...

(vianews) - the market ended the session with cnova (cnv.pa) jumping 13.74% to €3.89 on tuesday while cac 40 slid 0.46% to €7,339.27.

cnova's last close was €3.42, 42.23% under its 52-week high of €5.92.

about cnova

cnova n.v. operates as an e-commerce company in france and western europe. the company offers home appliances, consumer electronics, computers, home furnishings, and leisure and personal goods through its cdiscount.com website. it also operates cdiscount voyages, a travel platform; cdiscount billetterie, a ticketing platform; cdiscount energie for home energy; cdiscount mobile for cell phone plans; cdiscount advertising, a digital marketing solution; octopia for turnkey marketplace solutions to retailers and e-merchants; and c-logistics and c chez vous for transportation and logistics services. the company was founded in 1998 and is headquartered in amsterdam, the netherlands. cnova n.v. is a subsidiary of casino, guichard-perrachon s.a.

earnings per share

as for profitability, cnova has a trailing twelve months eps of €-0.28.

revenue growth

year-on-year quarterly revenue growth declined by 29.2%, now sitting on 1.7b for the twelve trailing months.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, cnova's stock is considered to be oversold (<=20).

moving average

cnova's worth is way higher than its 50-day moving average of €3.08 and above its 200-day moving average of €3.80.

more news about cnova (cnv.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com